VIDEO: Visus enrolling patients for second trial of presbyopia drop
Click Here to Manage Email Alerts
LAS VEGAS — Visus Therapeutics completed one clinical trial for Brimochol PF, a once-daily drop for presbyopia, earlier this year and is currently enrolling patients for a second trial, a company executive said at Vision Expo West.
Visus CEO Ben Bergo told Healio that the preservative-free combination of carbachol and brimonidine outperformed both carbachol and brimonidine alone, “with approximately 50% of subjects recording a 20/40 or better improvement in their near vision out at 10 hours” in BRIO-I.
Bergo said the company anticipates “reaching full enrollment [for BRIO-II] at the end of this year, filing in the second half of 2024 and then looking forward to an approval in the second half of 2025.”
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts